XML 34 R50.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Revenue from Collaboration and License Agreements (Detail) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended 12 Months Ended
Dec. 31, 2013
Sep. 30, 2013
Jun. 30, 2013
Mar. 31, 2013
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Collaboration and license revenue $ 2,056 $ 2,766 $ 2,601 $ 3,108 $ 1,958 $ 738 $ 66,865 $ 2,481 $ 10,531 $ 72,042 $ 78,029
Novartis AG ("Novartis")
                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Collaboration and license revenue                 0 70,084 9,571
Merck & Co., Inc.
                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Collaboration and license revenue                 0   31,402
Biogen Idec
                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Collaboration and license revenue                 0   37,056
Bristol-Myers Squibb Company ("BMS") and Pfizer Inc. ("Pfizer")
                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Collaboration and license revenue                 4,042 1,958  
Bayer Pharma, AG ('Bayer") and Janssen Pharmaceuticals, Inc. ("Janssen")
                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Collaboration and license revenue                 3,876    
Lee’s Pharmaceutical (HK) Ltd (“Lee’s”)
                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Collaboration and license revenue                 194    
Daiichi Sankyo, Inc ("Daiichi")
                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Collaboration and license revenue                 2,419    
Licensing Agreements | Novartis AG ("Novartis")
                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Collaboration and license revenue                 0 53,846 7,692
Reimbursement of research and development expense                 0 16,238 1,879
Licensing Agreements | Merck & Co., Inc.
                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Collaboration and license revenue                     21,429
Reimbursement of research and development expense                 0   9,973
Licensing Agreements | Biogen Idec
                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Collaboration and license revenue                 0   37,056
Licensing Agreements | Bristol-Myers Squibb Company ("BMS") and Pfizer Inc. ("Pfizer")
                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Collaboration and license revenue                 4,042 1,958  
Licensing Agreements | Bayer Pharma, AG ('Bayer") and Janssen Pharmaceuticals, Inc. ("Janssen")
                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Collaboration and license revenue                 3,876    
Licensing Agreements | Lee’s Pharmaceutical (HK) Ltd (“Lee’s”)
                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Collaboration and license revenue                 194    
Licensing Agreements | Daiichi Sankyo, Inc ("Daiichi")
                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Collaboration and license revenue                 $ 2,419